LinkedIn
WebsiteIntroduction
GENPREX INC (NASDAQ: GNPX), known in Korean as 젠프렉스, is a clinical-stage gene therapy company headquartered in Austin, Texas. The firm develops non-viral, lipid-based nanoparticle platforms to deliver disease-fighting genes for oncology and diabetes. Its lead oncology candidate, REQORSA® (quaratusugene ozeplasmid), is designed to deliver tumor suppressor genes to non-small cell lung cancer cells. The diabetes programs, GPX-002 and GPX-003, aim to modify or replenish insulin-producing pancreatic cells.
| Metric | Value |
|---|---|
| Price (Oct. 15, 2025) | $0.5476 |
| Change since Jan. 1, 2025 | +116.87 % |
| Trading Volume | 62,346,147 shares |
| Exchange | NASDAQ (GNPX) |
Corporate Structure
Founded in 2009, Genprex employs between 11 and 50 staff, according to its LinkedIn profile. Under the leadership of President, Chief Executive Officer, and Chief Financial Officer Ryan M. Confer, the company integrates R&D, clinical operations, and regulatory affairs teams in Austin, while collaborating with academic and industry partners.
Gene therapy by Sangharsh Lohakare
Recent Developments and News
- September 12, 2025: Genprex filed a Form S-1 registration statement to register up to 25 million shares of common stock under the Securities Act of 1933. The filing indicates that Genprex may receive up to $10 million from sales to Lincoln Park Capital Fund, LLC under an existing purchase agreement.
- September 16, 2025: The SEC declared the S-1 effective, allowing Genprex to proceed with its planned equity sales. On the same day, the company filed a prospectus on Form 424B3 detailing the resale of shares by Lincoln Park and confirming $2.46 million had been received under the June 11, 2025 agreement.
- October 14, 2025: At the AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics, Genprex collaborators presented preclinical data for REQORSA® in ALK-EML4 translocated non-small cell lung cancer.
- 2025 American Diabetes Association 85th Scientific Sessions: Genprex partners presented preclinical research on GPX-002’s non-viral delivery approach to convert pancreatic alpha cells into insulin-producing beta-like cells.
Financial and Strategic Analysis
Genprex’s equity financing strategy centers on its June 11, 2025, Lincoln Park purchase agreement. Under that arrangement, the company may draw up to $10 million in capital without direct share issuance proceeds. The Form 424B3 prospectus indicates potential variability in share sales depending on market conditions. As of the September filings, the last reported Nasdaq sale price was $0.2718 per share.
Market Position and Industry Context
Within the biotechnology sector, Genprex operates in gene therapy for oncology and metabolic disease. The ONCOPREX® Delivery System is recognized as one of the first systemic, non-viral platforms administered intravenously for cancer in humans. REQORSA® has received FDA Fast Track designations for both non-small cell and small cell lung cancer, with an Orphan Drug designation granted for small cell lung cancer. The GPX-002 program utilizes an AAV vector via endoscopic infusion—a strategy aimed at addressing immune-mediated beta-cell loss in type 1 diabetes and replenishing beta cells in type 2 diabetes. Competition includes viral-vector gene therapy developers and companies focused on next-generation RNA and cell therapies.
tl;dr
On September 16, 2025, Genprex received SEC effectiveness for its Form S-1, allowing for up to 25 million new shares and potential proceeds of $10 million under its Lincoln Park agreement. The share price rose to $0.5476 by October 15, 2025, reflecting an increase of 116.87 % since January. On October 14, 2025, preclinical lung cancer data for REQORSA® was presented at the AACR-NCI-EROTC. The company intends to pursue further capital raises and anticipates additional clinical updates for its oncology and diabetes programs in upcoming quarters.
